Skip to main content
Have a personal or library account? Click to login
Molecular-Genetic Aspects of Breast Cancer Cover

Molecular-Genetic Aspects of Breast Cancer

Acta Medica Bulgarica
Volume 41 (2014): Issue 2 (December 2014)
By: ,   and    
Open Access
|Feb 2015
References

References

  1. 1. Ahn, J. Y. et al. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. - Cancer Res., 60, 2000, № 21, 5934-5936.
    Search in Google Scholar
  2. 2. Ai, L. et al. Ataxia-telangiectasia-mutated (ATM) gene in head and neck squamous cell carcinoma: promoter hypermethylation with clinical correlation in 100 cases. - Cancer Epidemiol. Biomarkers Prev., 13, 2004, № 1, 150-156.
    Open DOISearch in Google Scholar
  3. 3. Albain, K. S. et al. HER2 overexpression in Breast Cancer. - Genetech Inc., 1998.
    Search in Google Scholar
  4. 4. Allinen, M. et al. Mutation analysis of the CHK2 gene in families with hereditary breast cancer. - Br. J. Cancer, 85, 2001, № 2, 209-212.
    Open DOISearch in Google Scholar
  5. 5. Almond, N. et V. Rotter. Involvement of p53 in cell differentiation and development. - Biochim. Biophys. Acta /Reviews on Cancer, 1333, 1997, № 1, 1-27.
    Open DOISearch in Google Scholar
  6. 6. Angele, S. et al. Abnormal expression of the ATM and TP53 genes in sporadic breast carcinomas. - Clin. Cancer Res., 6, 2000, 3536-3544.
    Search in Google Scholar
  7. 7. Angelova, S. G. et al. CHEK2 gene alterations independently increase the risk of death from breast cancer in Bulgarian patients. - Neoplasma, 59, 2012, № 6, 622-630.
    Open DOISearch in Google Scholar
  8. 8. Bell, D. W. et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science, 286, 1999, № 5449, 2528-2531.
    Open DOISearch in Google Scholar
  9. 9. Bernstein, J. L. et al. ATM variants 7271T>G and IVS10-6T>G among women with unilateral and bilateral breast cancer. - Br. J. Cancer, 89, 2003, 1513-1516.
    Open DOISearch in Google Scholar
  10. 10. Bogdanova, N. et al. Association of two mutations in the CHEK2 gene with breast cancer. - Int. J. Cancer, 116, 2005, № 2, 263-266.
    Open DOISearch in Google Scholar
  11. 11. Børresen, A. L. et al. Breast cancer and other cancers in Norwegian families with ataxia-telangiectasia. - Genes Chromosomes Cancer, 2, 1990, № 4, 339-340.
    Open DOISearch in Google Scholar
  12. 12. Bozhanov, S. / Angelova S. et al. Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer. -J. Cancer Res. Clin. Oncol., 136, 2010, 1657-1669.
    Open DOISearch in Google Scholar
  13. 13. Brose, M. S. et al. Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program. - J. Natl. Cancer Inst., 94, 2002, 1365-1372.
    Open DOISearch in Google Scholar
  14. 14. Cable, P. L. et al. Novel consensus DNA-binding sequence for BRCA1 protein complexes. - Mol. Carcinog., 38, 2003, № 2, 85-96.
    Open DOISearch in Google Scholar
  15. 15. Campbell, l. G. et al. Mutation of the PIK3CA gene in ovarian and breast cancer. - Cancer Res., 64, 2004, 7678-7681.
    Open DOISearch in Google Scholar
  16. 16. Carr, J. A. et al. The association of HER-2/neu ampliffication with breast cancer recurrence. - Arch. Surg., 135, 2000, 1469-1474.
    Open DOISearch in Google Scholar
  17. 17. Chen, S. et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. - J. Clin. Oncol., 24, 2006, № 6, 863-871.
    Open DOISearch in Google Scholar
  18. 18. Cybulski, C. et al. A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland. - Breast Cancer Res. Treat., 102, 2007, № 1, 119-122.
    Open DOISearch in Google Scholar
  19. 19. de Jong, M. M. et al. Genes other than BRCA1and BRCA2 involved in breast cancer susceptibility. - J. Med. Genet., 39, 2002, 225-242.
    Open DOISearch in Google Scholar
  20. 20. Dobrovic, A. et D. Simpfendorfer. Methylation of the BRCA1 Gene in Sporadic Breast Cancer. - Cancer Res., 57, 1997, 3347-3350.
    Search in Google Scholar
  21. 21. Honrado, E. et al. Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. - Oncogene, 25, 2006, № 43, 5837-5845.
    Open DOISearch in Google Scholar
  22. 22. Iannuzzi, C. M. et al. ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. - Int. J. Radiat. Oncol. Biol. Phys., 52, 2002, № 3, 606-613.
    Open DOISearch in Google Scholar
  23. 23. Kastan, M. B. et J. Bartek. Cell-cycle checkpoints and cancer. - Nature, 432, 2004, № 7015, 316-323.
    Open DOISearch in Google Scholar
  24. 24. Kilinc, N. et M. Yaldiz. P53, c-erbB-2 expression and steroid hormone receptors in breast carcinoma: correlations with histopathological parameters. - Eur. J. Gynaecol. Oncol., 25, 2004, 5, 606-610.
    Search in Google Scholar
  25. 25. Kilpivaara, O. et al. CHEK2 variant I157T may be associated with increased breast cancer risk. - Int. J. Cancer, 111, 2004, 543-547.
    Open DOISearch in Google Scholar
  26. 26. Krasteva, M. E. et al. Breast cancer patients with hypermethylation in the promoter of BRCA1 gene exhibit favorable clinical status. - Neoplasma, 59, 2012, № 1, 85-91.
    Open DOISearch in Google Scholar
  27. 27. Krasteva, M. et al. Aberrant promoter methylation in p53 and ATM genes was not associated with sporadic breast carcinogenesis in Bulgarian patients. - J. BioSci. Biotech., 3, 2014, № 2, 105-109.
    Search in Google Scholar
  28. 28. Lacroix, M., R. A. Toillon et G. Leclercq. P53 and breast cancer, an update. - Endocr. Relat. Cancer, 13, 2006, № 2, 293-325.
    Open DOISearch in Google Scholar
  29. 29. Lavin, M. F. et S. Kozlov. ATM activation and DNA damage response. - Cell Cycle, 6, 2007, № 8, 931-942.
    Open DOISearch in Google Scholar
  30. 30. Lavin, M. F. The Mre11 complex and ATM: a two-way functional interaction in recognising and signaling DNA double strand breaks. - DNA Repair (Amst), 3, 2004, № 11, 1515-1520.
    Open DOISearch in Google Scholar
  31. 31. Lawler, J. et al. Thrombospondin-1 gene expression affects survival and tumor spectrum of p53- deficient mice. - Am. J. Pathol., 159, 2001, 1949-1956.
    Open DOISearch in Google Scholar
  32. 32. Li, S. et al. Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. - Nature, 406, 2000, № 6792, 210-215.
    Open DOISearch in Google Scholar
  33. 33. Lukas, C. et al. DNA damage-activated kinase Chk2 is independent of proliferation or differentiation yet correlates with tissue biology. - Cancer Res., 61, 2001, № 13, 4990-4993.
    Search in Google Scholar
  34. 34. Malkin, D. et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. - Science, 250, 1990, № 4985, 1233-1238.
    Open DOISearch in Google Scholar
  35. 35. Matsuoka, S. et al. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. - Proc. Natl. Acad. Sci. U S A, 97, 2000, № 19, 10389-10394.
    Open DOISearch in Google Scholar
  36. 36. Meijers-HeIjboer, H. et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. - Nat. Genet., 31, 2002, № 1, 55-59.
    Open DOISearch in Google Scholar
  37. 37. Muthuswamy, S. K. et al. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. - Nat. Cell Biol., 3, 2001, 785-792.
    Open DOISearch in Google Scholar
  38. 38. Offterdinger, M., S. M. Schneider et T. W. Grunt. Heregulin and retinoids synergistically induce branching morphogenesis of breast cancer cells cultivated in 3D collagen gels. - J. Cell Physiol., 195, 2003, 260-275.
    Open DOISearch in Google Scholar
  39. 39. Olivier, M. et al. The IARC TP53 database: new online mutation analysis and recommendations to users. - Hum. Mutat., 19, 2002, 607-614.
    Open DOISearch in Google Scholar
  40. 40. O’ DrIscoll M. et P. A. Jeggo. The role of double-strand break repair - insights from human genetics. - Nat. Rev. Genet., 7, 2006, № 1, 45-54.
    Open DOISearch in Google Scholar
  41. 41. Peto, J. et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. - J. Natl. Cancer Inst., 91, 1999, № 11, 943-949.
    Open DOISearch in Google Scholar
  42. 42. Pharoah, P. D., N. E. Day et C. Caldas. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. - Br. J. Cancer, 80, 1999, 1968-1973.
    Open DOISearch in Google Scholar
  43. 43. Rice, J. C., K. S. Massey-Brown et B. W. Futscher. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. - Oncogene, 17, 1998, 1807-1812.
    Open DOISearch in Google Scholar
  44. 44. Ross, J. S. et al. The Her-2/neu gene and protein in breast cancer: biomarker and target of therapy. - Oncologist, 8, 2003, 307-325.
    Open DOISearch in Google Scholar
  45. 45. Rudolph, P. et al. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. - J. Pathol., 187, 1999, 207-216.
    Open DOISearch in Google Scholar
  46. 46. Saal, L. H. et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. - Cancer Res., 65, 2005, 2554-2559.
    Open DOISearch in Google Scholar
  47. 47. Sansal, I. et W. R. Sellers. The biology and clinical relevance of the PTEN tumor suppressor pathway. - J. Clin. Oncol., 22, 2004, 2954-2963.
    Open DOISearch in Google Scholar
  48. 48. Seo, Y. R. et H. J. Jung. The potential roles of p53 tumor suppressor in nucleotide excision repair (NER) and base excision repair (BER). - Exp. Mol. Med., 36, 2004, № 60, 505-509.
    Open DOISearch in Google Scholar
  49. 49. Shaag, A. et al. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. - Hum. Mol. Genet., 14, 2005, № 4, 555-563.
    Open DOISearch in Google Scholar
  50. 50. Singh, B. et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. - Genes Dev., 16, 2002, 984-993.
    Open DOISearch in Google Scholar
  51. 51. Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. - Science, 235, 1987, 177-182.
    Open DOISearch in Google Scholar
  52. 52. Sodha, N. et al. Screening hCHK2 for mutations. - Science, 289, 2000, № 5478, 359.
    Open DOISearch in Google Scholar
  53. 53. Stoppa - Lyonnet, D. et al. Familial invasive breast cancers: worse outcome related to BRCA1 mutations. - J. Clin. Oncol., 18, 2000, 4053-4059.
    Open DOISearch in Google Scholar
  54. 54. Tuma, R. S. Trastuzumab trials steal show at ASCO meeting. - J. Natl. Cancer Inst., 97, 2005, 870-871.
    Open DOISearch in Google Scholar
  55. 55. Turner, N., A. Tutt et A. Ashworth. Hallmarks of ‚BRCAness‘ in sporadic cancers. - Nature Reviews of Cancer, 4, 2004, 814-819.
    Open DOISearch in Google Scholar
  56. 56. Weischer, M. et al. Increased risk of breast cancer associated with CHEK2*1100delC. - J. Clin. Oncol., 25, 2007, № 1, 57-63.
    Open DOISearch in Google Scholar
  57. 57. Wong, M. W. et al. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer. - Breast Cancer Res. Treat., 127, 2011, № 3, 853-859.
    Open DOISearch in Google Scholar
  58. 58. Xu, X., L. M. Tsvetkov et D. F. Stern. Chk2 activation and phosphorylation-dependent oligomerization. - Mol. Cell Biol., 22, 2002, № 12, 4419-4432.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.1515/amb-2014-0024 | Journal eISSN: 2719-5384 (formerly 0324-1750) | Journal ISSN: 0324-1750
Journal RSS Feed
Language: English
Page range: 67 - 79
Published on: Feb 6, 2015
Published by: Medical University - Sofia
In partnership with: Paradigm Publishing Services
Keywords:
breast cancer,
tumor suppressor genes,
proto-oncogenes,
mutations,
DNA hypermethylation,
clinical impact
Related subjects:
Medicine,
Clinical medicine,
Clinical medicine, other

© 2015 M. Krasteva, Sv Angelova, Zl Gospodinova, published by Medical University - Sofia
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 41 (2014): Issue 2 (December 2014)
Previous article
Next article